Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol
European Union (EU) pharmaceutical legislation known as the Clinical Trials Regulation entered into application on 31 January 2022. It aims to ensure the EU offers an attractive and favourable environment for carrying out clinical research on a large scale, with high standards of public transparency and safety for clinical trial participants.
On 31 January 2022, the Regulation repealed the Clinical Trials Directive (EC) No. 2001/20/EC and national implementing legislation in the EU Member States, which regulated clinical trials in the EU until the Regulation's entry into application.
A transition period applies to clinical trial submission under the Regulation.
Table of Contents
3. How to report a serious breach
4. Clarification on reporting requirements
5. Reporting serious breaches – Points to consider
6. Responsibilities of parties involved in the notification of a serious breach
7. General considerations for serious breaches
8. Possible actions taken by the EU/EEA Member States concerned (MSC)
Appendix I – Examples of serious breaches
Appendix II – Points to consider for sponsors in relation to the assessment of a breach
Appendix III a – Template form for reporting serious breaches
Appendix III b – Information to be submitted with a notification of a serious breach
Source: Medicines & Healthcare products Regulatory Agency, the UK.
Clinical Research News
Prochains essais cliniques
-
BeiGeneRecrutementTumeur solide avancéeAustralie
-
BayerRegeneron PharmaceuticalsRecrutementŒdème maculaire diabétique | Dégénérescence maculaire néovasculaire liée à l'âgeHongrie, Slovaquie, Tchéquie
-
Erasme University HospitalRecrutement
-
University of MinnesotaPas encore de recrutementSyndrome de la Tourette | Troubles du tic
-
University of MinnesotaNational Center for Advancing Translational Sciences (NCATS)Pas encore de recrutementAccident vasculaire cérébral | AVC ischémique | AVC hémorragiqueÉtats-Unis
-
Beijing Tiantan HospitalPas encore de recrutementAdénome pituitaire | Tumeur neuroendocrine hypophysaire
-
Memorial Sloan Kettering Cancer CenterRecordati Pharmaceutical companyRecrutement
-
Centre Hospitalier Universitaire de BesanconPas encore de recrutementCirrhose | Péritonite bactérienne spontanéeFrance
-
NICHD Neonatal Research NetworkNational Heart, Lung, and Blood Institute (NHLBI)Pas encore de recrutementSyndrome cardiaque post-ligatureÉtats-Unis
-
Assiut UniversityPas encore de recrutement
-
Pharvaris Netherlands B.V.Pas encore de recrutement
-
University Hospital, BordeauxPas encore de recrutement